Optimizing sheep B-cell epitopes in Echinococcus granulosus recombinant antigen P29 for vaccine development.
| Autor: | Yang J; Center of Scientific Technology, Ningxia Medical University, Yinchuan, China.; Ningxia Key Laboratory of Prevention and Treatment of Common Infectious Diseases, Ningxia Medical University, Yinchuan, China., Lv Y; Ningxia Key Laboratory of Prevention and Treatment of Common Infectious Diseases, Ningxia Medical University, Yinchuan, China.; School of Basic Medicine, Ningxia Medical University, Yinchuan, China., Zhu Y; Ningxia Key Laboratory of Prevention and Treatment of Common Infectious Diseases, Ningxia Medical University, Yinchuan, China.; School of Basic Medicine, Ningxia Medical University, Yinchuan, China., Song J; Center of Scientific Technology, Ningxia Medical University, Yinchuan, China.; Ningxia Key Laboratory of Prevention and Treatment of Common Infectious Diseases, Ningxia Medical University, Yinchuan, China., Zhu M; Center of Scientific Technology, Ningxia Medical University, Yinchuan, China.; Ningxia Key Laboratory of Prevention and Treatment of Common Infectious Diseases, Ningxia Medical University, Yinchuan, China., Wu C; Institute of Immunology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China., Fu Y; Qinghai Academy of Animal Sciences and Veterinary Medicine, Qinghai University, Xining, China., Zhao W; Center of Scientific Technology, Ningxia Medical University, Yinchuan, China.; Ningxia Key Laboratory of Prevention and Treatment of Common Infectious Diseases, Ningxia Medical University, Yinchuan, China., Zhao Y; Center of Scientific Technology, Ningxia Medical University, Yinchuan, China.; Ningxia Key Laboratory of Prevention and Treatment of Common Infectious Diseases, Ningxia Medical University, Yinchuan, China. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in immunology [Front Immunol] 2024 Aug 14; Vol. 15, pp. 1451538. Date of Electronic Publication: 2024 Aug 14 (Print Publication: 2024). |
| DOI: | 10.3389/fimmu.2024.1451538 |
| Abstrakt: | Background: Echinococcus granulosus is a widespread zoonotic parasitic disease, significantly impacting human health and livestock development; however, no vaccine is currently available for humans. Our preliminary studies indicate that recombinant antigen P29 (rEg.P29) is a promising candidate for vaccine. Methods: Sheep were immunized with rEg.P29, and venous blood was collected at various time points. Serum was isolated, and the presence of specific antibodies was detected using ELISA. We designed and synthesized a total of 45 B cell monopeptides covering rEg.P29 using the overlap method. ELISA was employed to assess the serum antibodies of the immunized sheep for recognition of these overlapping peptides, leading to the preliminary identification of B cell epitopes. Utilizing these identified epitopes, new single peptides were designed, synthesized, and used to optimize and confirm B-cell epitopes. Results: rEg.P29 effectively induces a sustained antibody response in sheep, particularly characterized by high and stable levels of IgG. Eight B-cell epitopes of were identified, which were mainly distributed in three regions of rEg.P29. Finally, three B cell epitopes were identified and optimized: rEg.P29 Conclusion: Three B-cell epitopes were identified and optimized, and the efficacy of these epitopes was significantly enhanced by tandem connection, which indicated the feasibility of tandem peptide vaccine research. This laid a solid foundation for the development of epitope peptide vaccine for Echinococcus granulosus . Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Yang, Lv, Zhu, Song, Zhu, Wu, Fu, Zhao and Zhao.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|